A Two Part, Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-7145 in Patients With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II).

Trial Profile

A Two Part, Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-7145 in Patients With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 02 May 2017

At a glance

  • Drugs MK 7145 (Primary) ; Furosemide; Torasemide
  • Indications Cardiovascular disorders; Heart failure
  • Focus Pharmacokinetics
  • Sponsors Merck & Co
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Feb 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 11 Jun 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top